Milestones Payments. Subject to the terms and conditions of this Agreement, Trevi will pay Penwest a milestone payment upon the first occurrence of each of the following events, no later than [**] after the occurrence of the event:
Milestones Payments. Roche Bioscience shall pay Tularik the following amounts within thirty (30) days after each occurrence of the following events. Each payment under this Section 9.4.1 shall be made for, and only for, the first Roche Bioscience Compound directed against each particular Target that achieves such milestone. Payment Milestone ------------------------------------------------------------------------------ [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] Roche Bioscience shall notify Tularik of the occurrence of each milestone for each Roche Bioscience Compound. Such milestone payments shall be non-refundable [ * ]. Further milestone payments shall not be paid with respect to any particular Roche Bioscience Compound if it [ * ]. If a Roche Bioscience Compound is developed for additional Roche Bioscience Indications, [ * ]. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Milestones Payments. 20 9.4.2 Additional Clinical Milestones........................... 21 9.4.3
Milestones Payments. Following the Second Restated Effective Date, Amicus will make milestone payments to GSK with respect to each Product in the Expanded Major Market Countries as set forth below. Amicus will pay to GSK the milestone payments set out below following the first achievement by Amicus, its Affiliate or Sublicensee of each of the corresponding milestone events that are achieved after the Second Restated Effective Date, such milestone payment to be made by Amicus to GSK no later than sixty (60) days following the receipt of an invoice from GSK therefor. Amicus shall notify GSK in writing promptly, but in no event later than ten (10) calendar days after the first achievement of each of the following milestone events, and no invoice for payment of a milestone shall be sent by GSK to Amicus as provided herein prior to GSK’s reasonable determination that the corresponding milestone event has been achieved. Each of the following milestone payments shall be payable only once with respect to the first Product (other than a Co-Formulation Product) to achieve such milestone event, regardless of the number of times such Product or any other Product achieves the milestone event, and no milestones shall be paid or payable by Amicus for milestone events that are not achieved after the Second Restated Effective Date. ******.
Milestones Payments. As additional consideration for the grant of rights under this Agreement, and on the terms and subject to the conditions set forth herein, in the event that the following milestone events (each a “Milestone Event” and collectively, the “Milestone Events”) are achieved by OV, its Affiliates, or permitted sublicensees following the expiration of the R-Pharm Option Term (where R-Pharm has not entered into a Reacquistion Agreement), then OV shall notify R-Pharm thereof in writing within five (5) Business Days (and R-Pharm shall promptly issue an invoice for the applicable Milestone Payment), and OV shall pay to R-Pharm the corresponding milestone payment associated with the applicable Milestone Event as set forth below (each a “Milestone Payment” and collectively the “Milestone Payments”) within thirty (30) days of receipt of an invoice issued by R-Pharm in respect of such Milestone Payment.
a) Upon receipt of Regulatory Approval for the Product for the treatment of the first Indication in the first country in the Territory, [***]; and
b) Upon receipt of Regulatory Approval for the Product for the treatment of each additional Indication in the first country in the Territory for each such additional Indication, [***] for each such Indication.
Milestones Payments. For the purpose of milestone payments, ADCT shall notify ADAGENE of the occurrence of any relevant milestone and shall pay ADAGENE within thirty (30) days of the milestone occurrence.
Milestones Payments. CPI shall make payments to SVI for development of a Royalty Product in accordance with the milestones identified generally below, and described with more particularity in the Project Plan (the “Milestones”). Notwithstanding Section 4(A), 4(B) and 4(C) below, a Milestone Payment is due and payable only if (x) the New Lead is a Royalty Product (i.e., covered by an issued Royalty Patent), and (y) the License Agreement is in full force and effect on the date such Milestone Payment would otherwise become due. If a New Lead that was not a Royalty Product at the time a Milestone Payment otherwise would have been due (as provided below) later becomes a Royalty Product upon issuance of a Royalty Patent, CPI will retroactively make the applicable Milestone Payment(s) to SVI (provided it has not already made such payment(s)) within forty-five (45) days of final determination that such New Lead is a Royalty Product, pursuant to Section 3 above.
Milestones Payments. Following the effective date of any such termination by Amicus pursuant to Section 13.2 or by GSK pursuant to Section 13.3, Amicus will make milestone payments to GSK with respect to each Terminated Product and the Affected Area, as set forth in this Section 14.3.3(a). Amicus will pay to GSK the milestone payments set out below following the first achievement by Amicus, its Affiliate or Sublicensee of each of the corresponding milestone events that are achieved after the effective date of such termination, such milestone payment to be made by Amicus to GSK no later than ****** following the receipt of an invoice from GSK therefor. Amicus shall notify GSK in writing promptly, but in no event later than ****** after the first achievement of each of the following milestone events, and no invoice for payment of a milestone shall be sent by GSK to Amicus as provided herein prior to GSK’s reasonable determination that the corresponding milestone event has been achieved. Each of the following milestone payments shall be payable only once with respect to the first Terminated Product (other ****** - Material has been omitted and filed separately with the Commission. than a Co-Formulation Product) to achieve such milestone event, regardless of the number of times such Terminated Product or any other Terminated Product(s) achieves the milestone event, and no milestones shall be paid or payable by Amicus for milestone events that are not achieved after the effective date of such termination. For clarity, no milestone payments shall be made with respect to a Terminated Product that is a Co-Formulation Product. 1.****** ****** 2.****** ****** 3.****** ****** 4.****** ****** 5.****** ****** For purposes of Milestone 4 and Milestone 5 in the table set forth above and the calculation of the royalty tiers in the table set forth in Sections 14.3.3 (b)(i)(a) below, if the Terminated Product(s) is a Product(s) other than a Co-Formulation Product, the Net Sales of all such Terminated Products in the applicable Expanded Major Market Country ******.
Milestones Payments. 5.1. Subject to the other terms of this Agreement and Prima BioMed performing all its respective obligations under this Agreement, Neopharm shall pay the following one-time milestone payments to Prima BioMed, within [***] after Neopharm notify Prima BioMed in writing that the responding milestone event set forth below has been achieved:
5.2. [***] due and payable upon completion of Registration of the first Product in the Territory.
5.3. [***] due and payable upon the first time that the Net Selling Price of the first Product in the Territory per a full calendar year is above [***].
Milestones Payments. In partial consideration of the rights granted herein, when each Licensed Product first achieves in any country in the Territory the milestone events set forth below (each such event, a “Milestone Event”), iBio shall pay to RubrYc the following irrevocable, non-refundable, non-creditable milestone payments (each such payment, a “Milestone Payment”) within sixty (60) days of the achievement of the corresponding Milestone Event. Milestone Event Milestone Payment (U.S. Dollars) Phase I Clinical Study, 5th patient dosed [***] Phase II Clinical Study, 5th patient dosed [***] Phase III Clinical Study, 5th patient dosed, cash or iBio Stock at iBio’s discretion as elected on or prior to the date that is 30 days after delivering notice of such Milestone Event occurring [***] First Commercial Sale, cash or iBio Stock at iBio’s discretion as elected on or prior to the date that is 30 days after delivering notice of the First Commercial Sale occurring [***] Milestone Payments shall be payable (by iBio) regardless of whether the applicable Milestone Event was achieved by iBio or by another Selling Entity (or by a successor or assign of any of them) (provided that, for clarity, the foregoing reference to “successor or assign” does not limit the application to a Party’s successors or assigns of any other provision of this Agreement where “successor or assign” is not expressly stated). For the avoidance of doubt, (i) each Milestone Payment shall be payable on the first occurrence of the corresponding Milestone Event, and (ii) none of the Milestone Payments shall be payable more than once. For the avoidance of doubt, there are four (4) Milestone Payments in this Section, and the maximum amount to be paid by iBio pursuant to this Section is $15,000,000.
